Table 2.
Variables | Median survival time |
Std. Error of the Median |
95% CI of the Median | |
Lower bound Upper bound | ||||
Type of health facilities | ||||
Hospital | 19 | 1.39 | 16 | 24 |
Health center | 23 | 1.12 | 12 | 39 |
Sex | ||||
Male | 21 | 1.89 | 18 | 30 |
Female | 18 | 1.98 | 12 | 26 |
Residence | ||||
Urban | 20 | 1.89 | 16 | 24 |
Rural | 21 | 1.65 | 15 | 37 |
Disclosure status | ||||
Disclosed | 24 | 1.40 | 18 | 30 |
Not disclosed | 18 | 1.32 | 15 | 24 |
Substance use | ||||
Yes | 18 | 1.53 | 12 | 27 |
No | 23 | 1.85 | 18 | 31 |
Time since HIV diagnosis | ||||
≤3 Years | 18 | 1.03 | 14 | 23 |
>3Years | 24 | 3.29 | 19 | 42 |
Duration on ART (months) | ||||
<12 | 9 | 0.28 | 7 | 11 |
≥12 | 24 | 2.41 | 20 | 31 |
Baseline WHO clinical stage | ||||
Mild WHO stage | 24 | 3.50 | 16 | 33 |
Advance stage | 20 | 1.40 | 15 | 24 |
Past OI before HARRT initiation | ||||
Yes | 17 | 0.56 | 12 | 23 |
No | 24 | 0.58 | 20 | 33 |
Baseline weight | ||||
≥ 50 Kg | 23 | 2.54 | 8 | 35 |
< 50 Kg | 20 | 2.24 | 18 | 24 |
Baseline BMI | ||||
<18.5 | 19 | 2.34 | 12 | 24 |
≥18.5 | 24 | 1.75 | 18 | 35 |
Functional status | ||||
Working | 23 | 1.94 | 12 | 30 |
Ambulatory | 36 | 3.84 | 18 | 44 |
Bedridden | 18 | 1.49 | 12 | 24 |
Baseline CD4 Count | ||||
≥200cells/mm3 | 24 | 1.05 | 19 | 36 |
<200 cells/mm3 | 18 | 1.55 | 14 | 23 |
Cotrimoxazole preventive therapy | ||||
Yes | 24 | 2.99 | 18 | 36 |
No | 18 | 0.49 | 14 | 21 |
Isoniazid preventive therapy | ||||
Yes | 19 | 2.52 | 15 | 27 |
No | 21 | 1.62 | 17 | 30 |
Adherence level | ||||
Good | 24 | 2.01 | 19 | 43 |
Fair | 20 | 1.68 | 14 | 27 |
Poor | 18 | 0.39 | 12 | 21 |
Initial regimen substitution | ||||
Yes | 23 | 2.16 | 17 | 30 |
No | 20 | 1.7 | 14 | 24 |
First line regimen started | ||||
Nevirapine based | 24 | 3.03 | 17 | 39 |
Efavirenz based | 20 | 1.29 | 15 | 24 |